Wellgistics and Datavault AI ink $4 billion deal to build new health platform

(P1) Wellgistics Health Inc. (NASDAQ: WGRX) and Datavault AI Inc. (NASDAQ: DVLT) are moving to create a vertically integrated healthcare platform named DelivMeds AI, combining pharmacy optimization AI and blockchain in a series of transactions valued at approximately $4 billion. The deal intends to build a unified data and delivery system, challenging the fragmented structure of the current US healthcare market.

(P2) "Vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale," said Gerald Commissiong and Prashant Patel, interim co-Chief Executive Officers of Wellgistics Health, in a joint letter to shareholders. "We believe it is not a question of whether the industry adopts blockchain-based infrastructure, but when - and who is positioned to provide it."

(P3) The formation of DelivMeds AI is built on three pillars announced May 20. It includes an expanded license for Datavault AI’s PharmacyChain(TM) blockchain platform, the acquisition of QOLPOM’s intellectual property for biometric verification and drone logistics, and a controlling stake in patient-engagement company Tollo Health. The combined entity will integrate Wellgistics' EinsteinRx AI platform with these new capabilities.

(P4) For investors, the move represents a bet that owning the entire chain—from data infrastructure and patient verification to the final patient relationship—will become the most valuable position in healthcare. Wellgistics is restructuring to support this new phase, recently announcing a 1-for-50 reverse stock split effective May 26, 2026, to regain compliance with Nasdaq's minimum bid price requirement and attract institutional capital.

A Three-Layered Strategy

The company's strategy connects previously separate parts of the healthcare workflow into a single thesis. The core belief is that the pharmacy is the most critical and underused touchpoint for data collection and patient interaction. Wellgistics aims to extend its existing network of 6,500 pharmacies and over 200 manufacturers both upstream into data infrastructure and downstream into direct patient care.

The expanded Datavault AI license provides the foundational data layer, using blockchain tokenization to turn fragmented health information into a verifiable and exchangeable asset. The acquisition of the QOLPOM patent portfolio adds the verification layer, a crucial component for ensuring the integrity of the tokenized health data through remote biometric patient authentication and pharmacodynamic monitoring.

From Data to Delivery

The controlling interest in Tollo Health provides the patient-facing layer. Through programs like "Health Lives Here," developed in partnership with NFL Alumni Health, the company will engage directly with patients, such as those on GLP-1 drugs managing muscle loss. This will generate real-world data on adherence and outcomes that flows back into the EinsteinRx platform, creating a closed loop where data continuously informs care.

QOLPOM's IP also introduces a potential future solution for last-mile prescription delivery using drones capable of biometric patient verification. This could be particularly impactful for serving rural communities and for the collection of diagnostic specimens. By integrating these components, Wellgistics is building what it hopes will be the essential infrastructure for the next decade of healthcare, moving beyond single-point solutions to own the underlying data fabric.

This article is for informational purposes only and does not constitute investment advice.